cancer services annual report 2011 - infirmary health · unit offers continuous nursing assessment,...
TRANSCRIPT
Cancer Services
More, devoted to your care.www.mobileinfirmary.org
Cancer Services Annual Report 2011(reporting 2010 data)
TABLE OF CONTENTS
2010 Cancer Committee Members Cancer Services Departments Cancer Registry Oncology Unit Breast Center Pathology Department Radiology Department Special Studies Improved Pancreatic Fistula Rate after Laparoscopic Distal Pancreatectomy: Parenchymal Division with the use of Saline-Coupled Radiofrequency Ablation Dr. Lee Thompson, M.D. Selective Internal Radiation Therapy (SIRT) Dr. Roger Tart, M.D. Dr. Brandon Peters, M.D. Cancer Registry Summary & Data Cancer Registry Summary Cancer Registry Data Contacts
2010 Cancer Committee Members
Physician Members
Lee Thompson, M.D. (Chairman/ACoS Liason)……….. Medical Oncology
Michael Finan, M.D. (Vice-Chairman)…………………. Surgical Oncology
David Clarkson, M.D……………………………………… Hematology Oncology
John Russell, M.D. ………………………………………… Radiation Oncology
Eddie Reed, M.D. …………………………………………. Hematology Oncology
Robert Donnell, M.D. ……………………………………… Pathology
Mark McCaslin, M.D. ……………………………………... Radiology
Matthew Eves, M.D. ……………………………………… Gastrointestinal
Gerhard Boehm, M. D. …………………………………… General Surgery
Thomas Butler, M.D……………………………………….. Hematology Oncology
Edward Flotte, M. D………………………………………. Neurosurgeon
Lorie Fleck, M. D…………………………………………. Urologist
Robert Percy, M.D………………………………………… Pulmonologist
Cancer Services
Cancer Registry
Pamela Tillman, CTR, Team leader
The cancer registry department is staffed by two full-time cancer registrars, 1 full time
follow up clerk and one team leader. Currently 2 registrars are certified tumor registrars
as well as the team leader. The registry serves as a support system to other cancer service
departments providing a comprehensive cancer database with clinically relevant data for
use in patient management, program planning, research and education, etc. This database
continues to grow into a fundamental cancer information resource. The comprehensive
data set is collected by the cancer registrars on all newly diagnosed cancer patients and
provides the opportunity for extensive data analysis. There is constant surveillance of the
data internally through an ongoing quality control program with physician supervision,
and externally through annual critique of the data by the Alabama Statewide Cancer
Registry and the National Cancer Data Base of the American College of Surgeons.
Requests for aggregate cancer data related to incidence, practice patterns, treatment
trends, survival, etc. should be directed to the cancer registry at (251) 435-4583.
Oncology Unit
S.L. Willis-Turner, Manager
The oncology unit at Mobile Infirmary Medical Center is designed exclusively for the care and
management of patients with cancer or patients who have chosen end of life care. There are 30
beds on the unit which includes; five suite rooms and three large private rooms. This full-service
unit offers continuous nursing assessment, pre- and post-operative monitoring, administration of
chemotherapy and blood products, maintenance of vascular access devices, and pain
management. Comfort and patient satisfaction are priority focuses of the unit.
The oncology unit strives to ensure that our patients and our families are satisfied with the care
they receive during their stay. One of the main goals of the unit is to continue to increase overall
patient satisfaction. Routine visits to each patient are made by the manager, team leader, or the
charge nurse. Patients and family members are continuously encouraged to verbalize any
concerns they have regarding the care they receive during their stay. These concerns are
immediately addressed.
The staff performs hand-off communication at the bedside of the patient. At this time the plan of
care for the day, including patient goals are discussed. The patient and/or family members, at the
discretion of the patient, may participate in the plan of care and/or goals for the day.
The registered nurses, who include OCN staff, receive extensive education and training on the
administration of chemotherapy and the competency is assessed bi-annually. This education
includes the patho physiology of cancer, concepts of cell division and the action of
chemotherapy on the cells, recognition and management of side effects and symptoms,
prevention and management of extravasations, safe handling, dosage calculation, oncological
emergencies, patient education, and resources available. The staff also receives education on
chemotherapy precautions, radiation safety, infection control, age-appropriate care, and palliative
care during their unit orientation.
A major emphasis for the staff is provision of education to the patient and the family. A multi-
disciplinary approach is utilized to provide such patient education. Methods used include verbal
instructions, demonstrations, written material, and videos as applicable. Recognizing that
discharge planning begins on the day of admission, learning needs are assessed on admission and
throughout hospitalization. The philosophy of the oncology unit is that by providing the patient
and family with adequate education regarding their diagnosis and treatment plan, that they are
better able to understand and manage their care.
Holistic care is provided for the adult medical, surgical, gynecological, and radiation oncology
patient, as well as the hospice patient, by qualified healthcare personnel using a modified team
nursing for patient care. Resources available to the unit include a unit-based discharge
coordinator, in-house chaplain, dietitian, physical therapist, and a clinical pharmacist. Members
of the multi-disciplinary team meet daily to discuss the patient’s plan of care.
In order to deal with the patient and the family’s fears and emotions, the healthcare team must
look at each person individually. The patient and family experience an array of emotions. The
fear of dying, disability, disfigurement, dependence on others, and the overall disruption of their
lives are difficult to face. Being able to have someone to talk to about these feelings is
important for the overall emotional healing to allow the nurse to give the highest quality of care
to the patient and the family.
Hospice is a special way of caring for a person whose disease cannot be cured. It exists to
provide support and care for people who are terminally ill so they may live as fully and as
comfortably as possible. Hospice recognizes dying as a natural process and it neither hastens nor
postpones death. Hospice exists in the hope and belief that through appropriate care and the
promotion of a community sensitive to their needs, patients and families may be free to attain a
degree of mental and spiritual preparation that is satisfactory to them.
When patients sign consent to enter the hospice program, they voluntarily agree to palliative
(comfort, symptomatic) care in lieu of aggressive treatment (radiation therapy, chemotherapy,
surgery). This does not mean that the patient may never receive aggressive therapy again. The
patient may opt to revoke the hospice program. The patient and family are in control of the type
of treatment the patient chooses to receive. Hospice exists to make the most of each hour and
each day of one’s remaining life. The hospice staff provides these patients and their families
with companionship and emotional support as needed.
Mobile Infirmary Breast Center
Barbara Ledbetter, Director
The Breast Center at Mobile Infirmary and Eastern Shore has been awarded a three year
term of accreditation in Mammography as the result of a recent survey by the American
College of Radiology (ACR). The ACR headquartered in Reston, VA, awards
accreditation to facilities for the achievement of high practice standards after a peer-
review evaluation of the practice. Evaluations are conducted by board-certified
physicians and medical physicists who are experts in the field. They assess the
qualifications of the personnel and the adequacy of facility equipment. The surveyors
report their findings to the ACR Committee on Accreditation, which subsequently
provides the practice with a comprehensive report. The center also under went a State and
Federal yearly inspection without any citations or recommendations.
Mammography Services at Mobile Infirmary Medical Center are more effectively
identifying and treating the early signs of breast cancer while reducing discomfort to
patients through the use of added comfort measures, digital mammography and most
importantly through the expertise of our skilled clinical staff. We performed screening
and diagnostic mammograms for more than 18,000 women last year, in addition to
Stereotactic and Ultrasound Biopsies, Needle Localizations, Breast Ultrasound, Cyst
Aspirations, and Galactograms. The Infirmary Breast Center is also utilizing a
sophisticated computer program called CAD (Computer Aided Detection) that is linked
to the Digital Mammography system. It has been shown in studies to increase the
accuracy of Mammography by up to 20 percent. After the Radiologist has reviewed the
images on the monitor, cad is activated. The system scans the images and alerts the
Radiologist to take a second look by flagging any potentially suspicious areas. The
Radiologist then reviews these areas again to determine if they need further studies. Cad
is like having a second set of trained eyes reviewing every mammogram. Our goal is
providing the best possible care to women.
Breast cancer is the most common cancer among women in the United States and, after
lung cancer, is the second leading cause of cancer-related death. The chance of
developing invasive breast cancer at some time in a woman’s life is about 1 in 7. The
good news is breast cancer is highly treatable; over 90 percent of breast cancer patients
survive when cancer is detected in the early stages and treatment is begun promptly. It is
recommended that women start receiving yearly mammograms at the age of 40.
There are many exciting technologies being investigated in the field of breast imaging.
One new technology being developed is Tomosynthesis, an adjunct to digital
mammography. In conventional mammography, a 3-D structure (the breast) is evaluated
with a 2-D image. A major drawback of mammography is that structures can be
superimposed on a single image. This can result in cancers being hidden on the image or
can cause the false appearance of cancer, leading to unnecessary biopsies, etc.
Tomosynthesis is a 3-D digital technique that removes the effect of superimposed
structures by taking multiple low dose exposures of the breast and processing the
information into 1mm thick slices. This shows promise in improving detection of breast
cancer by mammography and decreasing the rate of false positive studies. All of this
work is in the hopes of detecting breast cancer at the earliest stage possible to allow
patients the best chance for a cure.
Mobile Infirmary Medical Center
Radiology Department
Anthony Mosley, Director
Implementation of Dynacad Software for Breast
MR. � DynaCAD Enterprise solution is a high performance Analysis Server with a
comprehensive set of advanced visualization tools for performing real time image
analysis of breast MRI studies. DynaCAD provides radiologist with a powerful
set of viewing and analysis tools for significantly improved workflow and
increased diagnostic confidence.
� This was purchased with the intent of being deployed system wide.
� Dynacad offers the latest advancement in Breast MR available.
Additional GE 7 Channel Breast Coil
� GE 1.5 Excite 7 Channel Breast Coil – Takes advantage of 8 channel system
capabilities including parallel imaging applications.
� Open apertures provide for lateral and medial access for MR breast
interventional procedures. Fully integrated biopsy and immobilization kit, Head
Rest and Pad for better patient comfort.
� The GE Signa Continuum is the industry’s leading obsolescence and investment
protection program.
� This upgrade is the latest offered by GE, and includes a new operator console
featuring a wide screen LCD monitor and improvements to operating systems
such as
� COSMIC – (Coherent Oscillatory acquisition for manipulation of Image Contrast)
A 3D imaging technique specifically tailored to C-spine studies. Its unique fluid-
weighted contrast yields improved visualization of the cervical nerve roots and
intervertebral disks.
� LAVA- (Liver Acquisition with Volume ) LAVA XV is a more reliable and
robust approach to high resolution liver imaging providing more extensive
coverage without time penalty.
� GE RXI Bariatric Radiographic and Fluoroscopy
system
� The Precision RXI is a remote controlled radiographic and fluoroscopy system.
The Precision RXI helps today’s bariatric practices meet the unique challenges of
imaging heavier patients with a high performance remote R&F system that helps
clinicians to confidently assess larger patients, while protecting the medical staff
from excessive radiation levels.
� Features that improve care for the bariatric patients included on this unit are
� Elevating tables – 78cm to 102cm allows easy access for patients who are unable
to ambulate without assistance.
� Variable SID – 115cm to 150cm the variable Source Image Detector allows
patients of significant size to be imaged in a new fashion previously not possible.
� Higher weight capacity of table 500lbs
� Employs CCD digital camera technology
� High frequency 80 KW generator
� 100 khz high frequency tube
� DSA – Digital Subtraction Angiography capabilities
� TO BE INSTALLED 2011
GE Innova 4100 Interventional Cath Lab � The Innova 4100 x-ray system incorporates GE’s exclusive Revolution solid state
digital detector to consistently provide excellent imaging performance through a
full range of diagnostic and interventional procedures.
� The Innova 4100 is a fully integrated imaging system that meets a wide range of
clinical needs for interventional and diagnostic image with excellent image
quality, real time processing, innovative dose management and improved
workflow.
� This package allows upgrades to remaining existing system as well as installation
of the newest technology GE offers. Enhancements will consist of the but not
limited to the following advancements - CT like images for RFA and biopsy
planning, increased table weight for bariatric patients, improved interventional
efficiency. Radiation does reduction software. 3-D road mapping and an
integrated UPS.
� THIS PROJECT IS CURRENTLY ONGOING
Pathology Department
The Mobile Infirmary Pathology department provides a full service surgical, cytological and
clinical pathology laboratory to assist in the diagnosis and treatment of cancer patients. In 2010
the Pathology department implemented synoptic reporting of cancer cases for all patients with
cancer resections. This method of reporting is based upon the recommendations of the Cancer
Committee of the College of American Pathology. Synoptic reporting insures that all
information required for staging is included within the pathology report, and provides
standardization of pathology reports, regardless of which pathologist performs the evaluation.
Improved Pancreatic Fistula Rate after Laparoscopic Distal Pancreatectomy:
Parenchymal Division with the use of Saline-Coupled Radiofrequency Ablation
Lee W. Thompson, MD FACS
Surgical Oncology
Cancer Surgery of Mobile, P.C.
3 Mobile Infirmary Circle, Ste. 305, Mobile, AL 36607
251-433-5557
William O. Richards, MD FACS
Professor and Chairman, Department of Surgery, University of South Alabama
2451 Fillingim Street, Mobile, AL 36617
251-471-7993
Jack W Rostas III, MD
General Surgery Resident, Department of Surgery, University of South Alabama
2451 Fillingim Street, Mobile, AL 36617
251-455-2560
Introduction: Post-operative pancreatic fistula (POPF) is the most common significant
complication after distal pancreatectomy (DP) and results in substantial morbidity. Many
different methods are available to divide the pancreatic parenchyma and achieve stump
closure, but demonstrating an improvement in the incidence of POPF has been difficult.
We report improved clinically significant fistula rates after hand-assisted laparoscopic DP
with the use of saline-coupled radiofrequency ablation (RFA) as the only device for
parenchymal division and stump closure.
Methods: A single institution retrospective review was conducted from October 2008 to
August 2010 evaluating all hand-assisted laparoscopic DP utilizing saline-coupled RFA
(Salient Surgical Technologies Endo SH2.0) as the exclusive method for division of the
pancreatic parenchyma and closure of the proximal pancreatic remnant. POPF was defined in
accordance with the International Study Group on Pancreatic Fistula. All significant
complications within the 30 day peri-operative period were also included.
Results: Twenty-one patients met the above criteria. One patient was excluded because
of loss to follow-up. One patient (5%) demonstrated a clinically significant (grade B)
POPF necessitating a prolonged duration of the operative drain. The only other
significant complication (5%) was a perforated gastric ulcer that required partial
gastrectomy. Average length of stay was 5.85 days, and average blood loss was 58mL.
Conclusion: The use of saline-coupled RFA alone for pancreatic parenchymal division
and closure after DP is safe and effective. Specifically, we report an overall significant
complication rate of 10%, consistent with previous reports, but with only a 5% rate of
clinically significant POPF.
Selective Internal Radiation Therapy (SIRT) Dr. Roger Tart, MD Dr. Brandon Peters, MD Our Selective Internal Radiation Therapy (SIRT) program has been in operation the past 3 years. This procedure involves treatment with Yttrium 90 sphere instillation into the hepatic arteries that course to the liver metastases or primary liver tumor. This allows a greater treatment dose to be delivered to the tumors as opposed to the background of normal liver. In this period, we have performed over 50 treatments averaging 1 to 2 patients a month. The most frequent diagnoses are neuroendocrine metastases (NET) and colorectal carcinoma (CRC) metastases. These patients are not surgical candidates and have failed all other effective treatment regimens. On follow-up, 83% of patients had improvement in tumor markers while 17% had an increase in marker values (CRC). Our patients had an average decrease in tumor volumes of 40% as measured on imaging at an average of 195 days. One patient had a significant increase in tumor size despite therapy (CRC). One patient had no significant change in tumor size (3%, undifferentiated cholangiocarcinoma), however, did have a significant decrease in the enhancement of the solid tumor components suggesting possible tumor necrosis and subsequent fibrosis. The complication rate was 4% for major complications and 4% for minor complications. Most of our patients have been discharged within 4 hours of the treatment without any patient having to be admitted to the hospital beyond the post procedure observation period. Each patient is individually assessed for appropriate inclusion criteria and has a thorough consultation with Dr Peters including a discussion concerning the individualized risks and benefits for their condition and tumor volume. For any additional information please contact Dr Brandon Peters or Dr Roger Tart in the Department of Radiology.
Cancer Registry Summary
Pamela Tillman, CTR
The cancer registry is a data system designed for the collection, management, and analysis of data
on cancer patients at Mobile Infirmary Medical Center. The registry department collects data on
all cancer-related diagnoses while maintaining patient confidentiality. Data such as patient
demographics, primary site, histology, diagnosis, staging, and treatment modalities are samples of
the data that is collected in the registry. Local data is combined with national data and provides a
means of studying cancer and treatment outcomes to assist in cancer control and prevention
efforts. Mobile Infirmary Medical Center’s data is submitted monthly to the Alabama State
Cancer Registry (ASCR) where it is evaluated for accuracy and completeness. The Mobile
Infirmary Medical Center cancer registry was awarded Gold Standard by the Alabama State
Cancer Registry for quality, completeness and timeliness of their data. The cancer registry also
participates in the National Cancer Database’s annual call for data.
The cancer registry information facilitates the preparation of patient care evaluation and quality
management studies which are important to the quality of cancer treatment. Registry data is
utilized for these special studies and reports. Multiple quality management studies were
performed during the year to evaluate and provide improvement opportunities to the cancer
programs.
Since the reference date of January 1, 1982, the cancer registry has accessioned 40,780 cases into
the database. In 2010, 1,911 cases were added to the database. 1,534 of these were analytic cases,
which are patients who are diagnosed and/or received their first course of treatment at Mobile
Infirmary Medical Center. The top five sites seen at Mobile Infirmary Medical Center in 2010
include prostate (201) representing 10.5% of the cases, breast (177) representing 9.2%, lung (173)
representing 9.1%, colorectal (152) representing 8.0%, and skin (106) representing 5.5%.
Annual follow-up on each analytic patient documents the quality and length of survival, as well
as, subsequent treatment information. The ongoing follow-up of the patient assesses the
effectiveness of diagnostic and treatment procedures. The registry records the current cancer
status of the patient, assuring continuing care. Currently the cancer registry maintains a follow-up
percentage of 95.5% for all lost to follow cases and 93.8% for the last five years.
Survival data generated by the registry can be used to reassure patients about the quality of their
cancer care in the managed care setting. The database is also a useful aid in the implementation of
clinical practice parameters, educational programs, and health resource delivery. All requests for
aggregate cancer data related to incidence, practice patterns, treatment trends, survival, etc.
should be directed to (251) 435-5889.
The cancer registrars at Mobile Infirmary Medical Center are credited with the compilation of this
annual report which reflects years of dedication to data standardization and accuracy
Sheet1
PRIMARY SITE TABULATION FOR 2010 CASES PRIMARY SITE TOTAL CLASS SEX STAGE
A N/A M F 0 I II III IV UNK N/A ALL SITES 1664 1392 272 825 839 162 358 317 160 175 353 139 ORAL CAVITY 30 15 15 22 8 0 2 2 2 5 19 0 LIP 0 0 0 0 0 0 0 0 0 0 0 0 TONGUE 5 1 4 4 1 0 0 0 0 1 4 0 OROPHARYNX 0 0 0 0 0 0 0 0 0 0 0 0 HYPOPHARYNX 2 1 1 2 0 0 0 0 0 1 1 0 OTHER 23 13 10 16 7 0 2 2 2 3 14 0 DIGESTIVE SYSTEM 328 274 54 176 152 37 61 60 45 54 62 9 ESOPHAGUS 17 14 3 14 3 1 5 4 2 2 3 0 STOMACH 21 18 3 13 8 1 7 2 1 4 4 2 COLON 144 115 29 72 72 21 23 30 22 19 29 0 RECTUM 48 37 11 30 18 11 9 6 9 4 8 1 ANUS/ANAL CANAL 8 7 1 3 5 2 0 0 1 1 4 0 LIVER 18 18 0 12 6 0 7 3 4 1 2 1 PANCREAS 48 44 4 23 25 0 5 12 4 18 9 0 OTHER 24 21 3 9 15 1 5 3 2 5 3 5 RESPIRATORY SYSTEM 230 183 47 134 96 2 40 6 36 63 82 1 NASAL/SINUS 0 0 0 0 0 0 0 0 0 0 0 0 LARYNX 13 8 5 12 1 1 4 0 2 2 4 0 LUNG/BRONCHUS 215 173 42 121 94 1 36 6 34 60 78 0 OTHER 2 2 0 1 1 0 0 0 0 1 0 1 BLOOD & BONE MARROW 31 22 9 16 15 0 0 0 0 0 0 31 LEUKEMIA 21 14 7 11 10 0 0 0 0 0 0 21 MULTIPLE MYELOMA 10 8 2 5 5 0 0 0 0 0 0 10 OTHER 0 0 0 0 0 0 0 0 0 0 0 0 BONE 1 1 0 0 1 0 0 0 0 0 1 0 CONNECT/SOFT TISSUE 18 17 1 9 9 0 0 1 2 0 14 1 SKIN 121 106 15 68 53 45 25 8 4 1 36 2 MELANOMA 119 105 14 67 52 45 25 8 4 1 35 1 OTHER 2 1 1 1 1 0 0 0 0 0 1 1 BREAST 216 177 39 11 205 32 58 42 14 7 63 0 FEMALE GENITAL 154 139 15 0 154 11 81 9 20 11 18 4 CERVIX UTERI 13 10 3 0 13 0 8 0 2 0 3 0 CORPUS UTERI 69 68 1 0 69 0 55 2 7 1 2 2 OVARY 40 35 5 0 40 0 11 4 9 8 8 0 VULVA 24 19 5 0 24 8 4 3 2 2 4 1 OTHER 8 7 1 0 8 3 3 0 0 0 1 1
Page 1
Sheet1
PRIMARY SITE TOTAL CLASS SEX STAGEA N/A M F 0 I II III IV UNK N/A
MALE GENITAL 227 208 19 227 0 0 5 168 21 14 19 0 PROSTATE 218 201 17 218 0 0 1 166 20 14 17 0 TESTIS 4 4 0 4 0 0 2 1 1 0 0 0 OTHER 5 3 2 5 0 0 2 1 0 0 2 0 URINARY SYSTEM 121 103 18 76 45 35 38 12 10 14 12 0 BLADDER 66 54 12 47 19 34 14 6 3 5 4 0 KIDNEY/RENAL 53 47 6 27 26 0 24 5 7 9 8 0 OTHER 2 2 0 2 0 1 0 1 0 0 0 0 BRAIN & CNS 27 27 0 11 16 0 0 0 0 0 0 27 BRAIN (BENIGN) 1 1 0 0 1 0 0 0 0 0 0 1 BRAIN (MALIGNANT) 20 20 0 10 10 0 0 0 0 0 0 20 OTHER 6 6 0 1 5 0 0 0 0 0 0 6 ENDOCRINE 37 35 2 12 25 0 21 4 4 0 2 6 THYROID 31 29 2 9 22 0 21 4 4 0 2 0 OTHER 6 6 0 3 3 0 0 0 0 0 0 6 LYMPHATIC SYSTEM 65 47 18 34 31 0 27 5 2 6 25 0 HODGKIN'S DISEASE 6 4 2 2 4 0 2 0 0 1 3 0 NON-HODGKIN'S 59 43 16 32 27 0 25 5 2 5 22 0 UNKNOWN PRIMARY 53 36 17 27 26 0 0 0 0 0 0 53 OTHER/ILL-DEFINED 5 2 3 2 3 0 0 0 0 0 0 5 Number of cases excluded: 3This report EXCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia
Page 2
Sheet1
Page 3
Sheet1
a cases
Page 4
0
50
100
150
200
250
300
10 - 19 20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 80 - 89
2010 AGE BY SEX
Male
Female
106
144
174160
317
357
135
0
50
100
150
200
250
300
350
400
0 I II III IV UNK N/A
2010 TNM STAGE DISTRIBUT ION
Data provided by MIMC Cancer Registry
2010 RACE DISTRIBUT ION
ASIAN
0.3%
BLACK
26.5%
WHITE
73.2%
Data provided by MIMC Cancer Registry
2010 SEX DISTRIBUT ION
MALE
49%
FEMALE
51%
Distribution of Cancer Cases by Counties in Alabama
MIMC Cancer Registry 2010 Data
County # of Cases County # of Cases
Baldwin 211 Houston 2
Butler 2 Jefferson 1
Choctaw 4 Marengo 7
Clarke 76 Mobile 973
Conecuh 5 Montgomery 1
Covington 4 Monroe 41
Dallas 3 Washington 45
Elmore 1 Wilcox 7
Escambia 18 Out of State 133
399,843
47.80%
52.20%
63.10%
33.40%
3.50%
88.10%
11.90%Source: US Census Bureau http://factfinder.census.gov/
White White White White Black Black Black Black
Male Male Female Female Male Male Female Female
Rate Count Rate Count Rate Count Rate Count
623.8 7787 452.3 6984 697.2 3088 424.5 2851
116 1436 63.7 1022 125.1 547 45.4 300
70.9 877 47.3 756 82 351 61.6 407
* * 146.5 2238 * * 145 982
* * 8 108 * * 9.5 64
151.6 1948 * * 251.1 1097 * *Rates are per 100,000 and age-adjusted to the 2000 U.S. (19 age groups) standard.
^ Statistic not displayed due to fewer than 6 cases.
Source: Alabama Statewide Cancer Registry, 2010
Alabama
Cancer Profile for Mobile County
Cervix
Prostate
Total Population
% Male
All Sites
Cancer Incidence in Mobile County 1999-2008
Mobile
% Female
Breast
Population 2000 Census
% White
% Black
% Other Races
% Under 65
% 65 and Older
Lung
Colorectal
Mobile County and Alabama Comparisons 1999-2008
Mobile
Alabama
Rate
492.9
76.0
53.9
143.1
9.8
152.9Rates are per 100,000 and age-adjusted to the
2000 U.S. (19 age groups) standard.
^ Statistic not displayed due to fewer than 6 cases.
Source: Alabama Statewide Cancer Registry, 2010
Source: Alabama Statewide Cancer Registry, 2010
Lung
177.8
Cervix
Prostate
Mobile
146.8
8.4
All Sites
Breast
Colorectal 60.4
Rate
524.9
83.4
0.0 100.0 200.0 300.0 400.0 500.0 600.0
All Sites
Lung
Colorectal
Breast
Cervix
Prostate
Age-adjusted rate per 100,000 people
Alabama Mobile
Mobile Infirmary Medical Center Numbers Mobile Infirmary Medical Center (251) 435-2400 Cancer Registry (251) 435-5889
Radiation Oncology (251) 435-3549 Oncology Unit (251) 435-4661 Breast Center (251) 435-5060 Infirmary Home Health Agency (251) 450-3300 Case Management (251) 435-3531 Social Services (251) 435-3566 PRO Health Fitness & Rehabilitation Center (251) 435-2010
Websites Mobile Infirmary Medical Center www.mobileinfirmary.org Cancer Surgery of Mobile www.cancersurgerymobile.com American Cancer Society www.cancer.org National Cancer Institute www.nci.nih.org American College of Surgeons www.facs.org Association of Community Cancer Centers www.accc-cancer.org
Mobile Infirmary Medical Center
Cancer Registry
July 5, 2011
P O Box 2144
Mobile, Alabama 36652
(251) 435-2400
www.mobileinfirmary.org
